Citigroup analyst David Lebovitz maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $389 to $382.
Citigroup Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $382
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.